Sanofi kicks off PhII test for RIPK1 inhibitor, triggering Denali milestone; Italian biotech flops key endpoint in muscular dystrophy study
Close to 3 years after Sanofi’s John Reed anted up $125 million in cash to bet on Denali’s RIPK1 inhibitor program, the pharma giant has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
